GHC - Garofalo Health Care S.p.A. is a leading group, in the field of private accredited healthcare, listed on the Euronext STAR segment of the Italian Stock Exchange and based in Rome, Italy. The qualities and strengths that make the Group unique are diverse and can be distinguished by the following characteristics:
Territorial diversification. GHC represents 28 centres of excellence located in some of the most prosperous regions of Northern and Central Italy: Piedmont, Lombardy, Veneto, Friuli Venezia Giulia, Liguria, Emilia Romagna, Tuscany, Lazio. The professionals and medical teams of each centre constantly and consistently collaborate with each other in terms of research activities and direct operating methods, with the aim of better protecting the patient’s health.
Sector diversification. GHCoffers a wide range of services and specializations, upholding high quality standards, and covering all sectors of the health and social care sector. From high-complexity surgery to medium- and low-complexity surgery, to emergency surgery and medicine, to clinical and interventional cardiology, to motor, neurological, cardiac and nutritional rehabilitation, to extended and intensive care units (RSA), to centres for patients in coma and persistent vegetative states, and to psychiatric and diagnostic centres.
Innovation and professionalism. GHCis characterized by the use of cutting-edge technologies, both for medical diagnostics with state-of-art machinery, and for medical equipment, including robotic-assisted surgery. Moreover, the presence of highly qualified staff and internationally renowned professionals, guarantee the highest quality of services and places the Group’s structures in a leading position for the entire scientific community.
Humanization of care. GHC places the patient at the centre of the healthcare system. Patients are considered in their entirety: their physical, psychological and social well-being, as well as their feelings, knowledge and experience of the disease, are taken into account. Diagnosis and treatment of diseases are provided according to appropriateness, timeliness, effectiveness, and the systematic and continuous nature of the disease, as required by the patient’s state of health. The patient is also kept adequately informed. In addition, GHC facilities are constantly committed to improving the physical accessibility, liveability, cleanliness and comfort of hospital rooms.
Training and scientific research. In GHC structures, staff receive continuous training and development. In addition, intensive research is carried out in collaboration with Italian and foreign research institutions and universities, in particular oriented towards highly complex specialties such as cardiac surgery, vascular surgery, orthopaedic traumatology, vertebral surgery, reconstructive surgery of the upper limbs, urology, internal medicine, diabetology and diabetic foot, including the treatment of psychiatric and eating disorders. Moreover, in GHC structures, key therapeutic protocols are defined for the management of infected patients and for the control of hospital infections.
Healthcare modernization. GHC constantly supports the modernization of its institutions by investing heavily in restructuring projects, and by expanding and creating new departments, in order to render its health facilities more effective and efficient, and also to improve the quality of patient care and hospitality.
The history of GHC - Garofalo Health Care S.p.A. - originated from the passion and courage of Raffaele Garofalo, a man born in 1921, driven by an underlying ideology based on a profound respect for human life; an exceptional surgeon, who decided to devote his entire life to the defence and protection of human life, in the firm belief that the patient must always be placed at the centre of the system. In this respect, he constantly supported the use innovation, striving for excellence in healthcare. In addition, Raffaele Garofalo was also a skilled entrepreneur who, starting from a simple dream, managed to lay the foundation for a solid and productive group.
As early as the 1950s, together with his two brothers, Antonio and Mario (also doctors), the young Raffaele, already an experienced surgeon, imitated a major entrepreneurial venture with the acquisition of important healthcare facilities located in the Lazio region, thereby creating the first private healthcare group in the region. But this was only the start of a journey that reached its peak at the end of the 1990s, when, Raffaele Garofalo, together with his daughter, Maria Laura, followed the path of territorial and sector diversification by acquiring healthcare facilities in various regions of Northern Italy.
This lead to the acquisition of Eremo di Miazzina in Verbania in the Piedmont region, a rehabilitation and social assistance structure. Subsequently, in May 2000, it was the turn of Villa Berica in Vicenza, a multi-speciality structure for acute care, equipped with a rehabilitation department. In August of the same year, the Hesperia Hospital of Modena, a special multi-speciality hospital for acute patients, mainly known for its Cardio-Thoraco-Vascular Department, was acquired. In 2002, the Group acquired Villa Garda in the province of Verona, a rehabilitation facility equipped with a nutritional rehabilitation and a cardiac rehabilitation department, the first European landmark for the treatment of eating disorders (anorexia, bulimia and obesity).
Raffaele Garofalo died in February 2006, but GHC’s growth path did not stop there. In 2008, the Rugani Nursing Home, today known as Rugani Hospital, was acquired in Siena. This is a multi-specialty structure for acute patients, equipped with a rehabilitation centre, as well as one for patients in a persistent vegetative state. Villa Von Siebenthal Nursing Home, located in Genzano, was also acquired in 2008. It is a residential facility dedicated to the treatment of patients with psychiatric disorders and drug addiction. During the same year, a piece of land was purchased in Gravellona Toce (Piedmont region), in an area without sanitary facilities, near an important motorway junction. The land was used to build the Raffaele Garofalo Institute, a new and important structure for recovery and functional rehabilitation.
In 2014, sector diversification was extended to the field of outpatient diagnostics with the acquisition of C.M.S.R. Veneto Medica, located in Altavilla Vicentina. In partnership with the Regional Health Service (SSR), the facility represents a centre of excellence in the field of diagnostic imaging and cardiology, through its use of advanced technology, high medical expertise and organizational efficiency.
In June 2017, it became part of the Garofalo business reality, owned by the Fides Group, directly or through subsidiaries and associated companies, of 11 social and healthcare facilities located in Genoa and in the Province of Genoa. It is one of the most important private healthcare and management services in the Liguria region, focusing mainly on physical therapy, motor and psychiatric rehabilitation, disability and long-term care.
In addition, after a few months, Garofalo strengthened its presence in the Emilia-Romagna region by taking over the Casa di Cura Prof. Nobili in the Bologna Province, a facility equipped with a medical department, a surgical unit, a dialysis room, a large outpatient diagnostic department, and a unit for initial/emergency care. The structure carries out the function of “ospedale per il territorio” (hospital for the territory).
In 2018, GHC began an important journey towards its listing on the Borsa Italiana S.p.A. Electronic Share Market. Despite adverse financial conditions and a spread of 350 basis points, the company was officially listed on 9 November 2018 with a share demand three times higher than supply. Moreover, the listing was based solely on an increase in share capital.
Entry into the Italian Stock Market subsequently led to a "Buy and Build" strategy aimed at consolidating the Group's positioning in the reference market. This further improved its economic and financial performance and strengthened its competitive positioning. In fact, not even a month after listing, the Group acquired 100% of the share capital of the company: Poliambulatorio Dalla Rosa Prati Srl., a Diagnostic Centre of excellence based in Parma, operating both as a public healthcare provider accredited by the Emilia-Romagna Region, and as a private healthcare provider. The company is able to handle about 600 patients a day. It provides specialist outpatient treatment, physiatry and physiotherapy services, outpatient surgery, diagnostic imaging and nuclear medicine; as well as efficient laboratory testing and has a department dedicated to dentistry. Subsequently, just 6 months after listing, the Group acquired Ospedali Privati Riuniti (OPR), another important private healthcare company in Emilia Romagna, with two accredited hospitals, both located in Bologna (Nigrisoli Private Accredited Hospital and Villa Regina Private Accredited Hospital), with a total of 170 authorized beds, of which 168 are accredited. This acquisition represents an operation of huge strategic value for GHC as it significantly strengthens its presence in Emilia-Romagna.
In June 2019, the Group’s Buy & Build strategy was further confirmed with the entry of three healthcare structures operating in the diagnostic imaging sector: Centro Medico San Biagio and Bimar in Portogruaro (Venice) whose acquisitions were completed in July 2019, and Castrense University Medical Centre in San Giorgio di Nogaro (Udine) whose acquisition were completed in September 2019. These acquisitions are of the utmost strategic value for GHC because, in addition to strengthening the Group’s presence in Veneto, they have also enabled the Group to enter a new, particularly wealthy region, Friuli-Venezia Giulia.
Immediately after in July 2019, through its subsidiary Hesperia Hospital in Modena, GHC acquired 100% of Aesculapio, an accredited polyclinic based in San Felice sul Panaro (province of Modena), the largest polyclinic centre in the northern area of Modena province. It is also considered a major regional health centre, operating both as a public healthcare provider accredited by the Emilia-Romagna Region, and as a private healthcare provider in the main branches of specialized outpatient healthcare.
A year later, in July 2020, GHC acquired 100% of the share capital of XRay One, a diagnostic centre for diagnostic radiology and specialist medicine, accredited by the National Healthcare System and located in Poggio Rusco, in the province of Mantua. Through this acquisition the Group takes its first step into Lombardy, a Region that continues to represent a reference point for Italian healthcare, moreover XRay One enjoys a positioning that will allow significant synergies to be achieved, thanks to the strategic proximity between the other GHC's facilities located in Veneto and Emilia-Romagna regions.
In February 2021, the binding agreement was signed for the purchase of the Clinica San Francesco in Verona, an European reference centre for robotic prosthetic orthopaedic surgery. The entry of the Clinic leads the Group to an increase in the specialist technologies available to the facilities and an enrichment of the Group’s clinical-surgical and scientific solutions. Also in the same year, in July, the acquisition of two additional facilities in Emila Romagna, the accredited private hospitals Domus Nova and San Francesco di Ravenna, which allow to cover the entire ridge of the region.
Today Garofalo Health Care S.p.A. is the first, and presently, the only private company listed in Italy in the healthcare sector, and ‘best in class’ both at the national and international level for management performance. The Group operates through 28 healthcare facilities of excellence. It is located in 8 of Italy's wealthiest regions and offers a wide range of services covering all areas of healthcare thanks to the diversity of its specialist services and to its use of state-of-art technologies and highly qualified staff.
HEALTH IS A PERSON’S MOST VALUABLE ASSET
This profound and fundamental conviction has always guided the path of Prof. Raffaele Garofalo, an exceptional surgeon who dedicated his whole life to the defence and protection of human life. It is also the guiding and inspiring principle of Lawyer Maria Laura Garofalo, GHC Managing Director, who now carries out the entrepreneurial activity started by her father, Prof. Raffaele Garofalo, and all his relatives and collaborators, who continue to operate within GHC facilities to carry out this vital mission.
Health is your most valuable asset. The most valuable, because, as a human being, it represents your future. Persons who risk losing this primary asset must be safeguarded, cared for, assisted and protected; they must be placed at the centre of a system in which therapies and diagnostics consider patients in their psycho-physical entirety, and which constantly aim at protecting this right.
For this reason, the professional and entrepreneurial activity of each institute aims at guaranteeing the excellence of health and social care services, by always keeping in step with the times both in terms of research and scientific knowledge, and in terms of technological innovations and the implementation of highly performing organizational processes, with a particular focus on the humanisation of care.
Via San Biagio 13 - 30025 - Fossalta di Portogruaro (VE)
Privacy – Responsabile Protezione Dati
Dott. Franco Cardin
Istitutional Review Board (IRB)
Il Comitato Scientifico di Gruppo opera per mezzo dell’Institutional Review Board (IRB), che ha l’obiettivo di formulare pareri di conformità a principi etici su protocolli clinici, studi e progetti di ricerca presentati dal Comitato Scientifico.
Qui di seguito il link per scaricare il Regolamento dell’Institutional Review Board
Il Presidente in carica dell’International Review Board è il Dr. Riccardo Dalle Grave
Composizione del Board:
- Dr.ssa Marzia Lugli (Chirurgia vascolare / Hesperia Hospital)
- Dr. Giorgio Beltrame (Chirurgia oculistica / Centro Medico San Biagio) Dr. Leonardo Osti (Chirurgia ortopedica / Hesperia Hospital)
- Prof. Maurizio Brausi (Urologia / Chirurgia robotica / Hesperia Hospital)
- Dr. Stefano Nistri (Cardiologia / CMSR)
- Dr. Alberto Cogo (Medicina interna / Villa Berica)
- Dr. Marcello Villanova (Neurologia / Nigrisoli – Ospedali Privati Riuniti) Dr. Marco Massa (Psichiatria / Villa del Principe-Gruppo Fides)
- Dr. Fabio Tumietto (Infettivologia / Hesperia Hospital)
- Dr.ssa Milena Calderone (Radiologia / CMSR)
- Dr. Marco Meli (Anestesia / Hesperia Hospital)
- Dr.ssa Tiziana Beniamini (Biologia / Poliambulatorio Dalla Rosa Prati) Dr.ssa Simona Calugi (Ricerca clinica / Villa Garda)
- Dr. Erjon Radeshi (Medicina legale)
- Prof. Giulio Marchesini Reggiani (Bioetica)
Di seguito la documentazione da inoltrare a firstname.lastname@example.org per la valutazione degli studi:
- Dichiarazione pubblica sul conflitto di interessi
- Documento informativo
- Informativa protezione dati personali
- Domanda di parere per la conduzione di uno studio non interventistico
- Descrizione dello studio (sinossi)
- Appropriatezza della Struttura in cui lo studio si svolgerà
- CV dello sperimentatore e di tutti i collaboratori coinvolti
- Eventuali coperture assicurative, ove necessario
- Eventuali modalità di finanziamento a favore degli sperimentatori, ove previste
CALENDARIO RIUNIONI IRB
Venerdì 16 Luglio 2021 - h.17.00
La ricerca scientifica in medicina ed in sanità è strettamente connessa con le attività cliniche (clinical trials) e gestionali (health services research) dirette alla prevenzione, cura e riabilitazione delle malattie, per promuovere la salute degli individui.
L’efficacia di ogni intervento preventivo, terapeutico o riabilitativo deve essere garantita, prima della sua attuazione, dall’evidenza scientifica di innocuità ed utilità medica, “evidence based medicine”, così come ogni modello organizzativo clinico, “evidence based governance”.
In ognuna delle strutture del Gruppo GHC, i medici generalmente affiancano ad una pratica clinica, sempre più orientata dal progresso scientifico e tecnologico, un’attività scientifica significativa, in collegamento con qualificati gruppi nazionali ed internazionali, con una grande produzione di articoli su riviste “indexate”, alcuni di essi con rilevanti livelli di produttività (H Index).
Per tale motivo nel 2018 è stato istituito il Comitato Scientifico di Gruppo con lo scopo di:
- mettere a disposizione dei clinici e dei ricercatori un «foro» per la condivisione e la sinergia delle loro attività scientifiche;
- agire come promotore di indirizzi comuni per la programmazione e presentazione di progetti di ricerca alle agenzie nazionali ed internazionali di finanziamento della ricerca medica e dei servizi sanitari;
- mappare le eccellenze presenti nelle strutture sanitarie del Gruppo GHC;
- identificare progetti di ricerca che possano essere sviluppati in ciascuna struttura sanitaria del Gruppo GHC;
- favorire la collaborazione e l’interscambio culturale attraverso specifici incontri di carattere scientifico;
- perseguire il miglioramento generale della qualità delle cure delle singole strutture sanitarie del Gruppo GHC.
Di seguito il link per la visione dello statuto del Comitato Scientifico
Il Presidente in carica del Comitato Scientifico è il Prof.Oscar Maleti.
Ne costituiscono componenti permanenti i Direttori Sanitari e i Direttori Scientifici delle Strutture del Gruppo ed almeno un esponente di ognuna delle discipline cliniche più rappresentative.